Unresolved issue: should patients with RA and a history of malignancy receive anti-TNF therapy?
Brar
Adarshdip
A
University of Manitoba, Winnipeg, Canada.
Hiebert
Timothy
T
El-Gabalawy
Hani
H
D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000209:etiology* / Q000276:immunology; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha